[ad_1]
Good news from the United States in the Vaccine for coronavirus. The American Pharmaceutical Company Modern in fact, it announced, announcing the results of the Phase 3 tests of the Cove study, that its candidate vaccine has shown an efficacy of 94.1% against Covid-19, which can reach 100% in severe cases. 30,000 volunteers participated in the analysis, including 196 cases of Covid-19, of which 30 severe. Today Moderna will also apply to the US drug authority. Fda authorization for emergency use, andEuropean Medicines Agency (Ema) of a conditional authorization. After that, once the approval arrives, the first doses could already be distributed in the United States, currently the first country in the world by the number of infections.
In the US Possible first doses for Christmas
The Vaccine Committee of the U.S. Drug Authority FDA is expected to meet on December 17 analyze the efficacy and safety data of Moderna’s mRNA-1273 Covid vaccine candidate. Distribution of the vaccine in the US will take place immediately after an Authorization for Emergency Use is secured – the identified date could be December 21, if deadlines are respected. Furthermore, by 2020, the company expects to have the availability of approx. 20 million doses of Covid mRNA-1273 vaccine in the United States, in addition to beginning production of 500 million to 1 billion doses globally in 2021. Moderna also announced new advancements aimed at ensuring that vaccine distribution, storage and handling can be accomplished using existing infrastructure .
“Our vaccine is a powerful tool against the pandemic”
“This positive analysis confirms the ability of our vaccine to prevent Covid-19 with an efficacy of 94.1% and, above all, the ability to prevent serious forms. We believe that our vaccine will provide a new and powerful tool that could change the course of this pandemic and help prevent serious illnesses, hospitalizations and deaths “, was the comment of Stéphane Bancel, CEO of Moderna, communicating the latest data from the phase 3 trial on the vaccine candidate. “I want to thank – he added – the thousands of participants in our Phase 1, Phase 2 and Phase 3 studies, as well as the staff of the clinical trial sites at the forefront of the fight against the virus. I would like again to thank our partners in Nih, Niaid, Barda and Operation Warp Speed who assisted us in the clinical development of mRna-1273. “
[ad_2]
